Dabrafenib (GSK2118436)

目录号：S2807

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
10mg	RMB 1056.75	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献21篇：

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )
Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

客户使用该产品的9个实验数据：

BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.
Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.
Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

Western blots for untreated, early, and late tumors.

Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.
Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.
Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MVfLbY5ie2ViQYPzZZk>				NUjJV5Z6UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BETEN\|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN	MYiyOFkxODZ5Mx?=
SK-MEL-28	NFnwZYpMcW6jc3WgRZN{[Xl?		NGnySW4yKGh?		M{\3dWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2=	NEn3eXkzPDlyME[3Ny=>
HepG2	NHfWU3hMcW6jc3WgRZN{[Xl?				NIXHO3lKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1?	MYSyOFkxODZ5Mx?=
COLO205	M{HzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV73Zo1mUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPNlA2KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xODdizszN	NX3MbGFuOjR7MEC2O\|M>
HepG2	MWTGeY5kfGmxbjDBd5NigQ>?		MlLxOFUhdWmw	MVfEUXNQ	NWnvbHdNUW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=>	MXOyOFkxODZ5Mx?=
HFF	NHm0WJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NESz[4syOCEQvF2=	NGjsUZE4OiCq	NUX3RopnTE2VTx?=	NFvZNINKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	MkexNlM5PDRyM{i=
SK-MEL-28	M3e0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	MVe3NkBp	NXnrbVVyTE2VTx?=	NHu2XFVKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iU1utUWVNNTJ6IHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yNEOg{txO	MXmyN\|g1PDB\|OB?=
A375P-F11	NHT1TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nBeFExKM7:TR?=	NHq2Ros4OiCq	MVnEUXNQ	MkTVTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF\|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=>	M2fHN\|I{QDR2MEO4
MALME-3M	M4L1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXSxNEDPxE1?	MYq3NkBp	M4XaZmROW09?	NGfI[lRKSzVyPUGgcm0>	M2DMZVI{QDR2MEO4
UACC-62	NITzXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXyxNEDPxE1?	NV3PPYhYPzJiaB?=	MoW0SG1UVw>?	MULJR\|UxRTFibl2=	MVGyN\|g1PDB\|OB?=
C32TG	NHvkXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCxNEDPxE1?	NWTWd2JVPzJiaB?=	MnjoSG1UVw>?	NEnaSZBKSzVyPUGgcm0>	MVmyN\|g1PDB\|OB?=
SK-MEL-1	M2Ljd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlntNVAh\|ryP	MlfFO\|IhcA>?	M3T5VWROW09?	NW\tUXF2UUN3ME2yJI5O	NXfPcFExOjN6NESwN\|g>
M14	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HjPVExKM7:TR?=	NE[5SlI4OiCq	M{HxfmROW09?	MWjJR\|UxRTJibl2=	MYqyN\|g1PDB\|OB?=
SK-MEL-28	M1u0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHySpUyOCEQvF2=	MVe3NkBp	Mm\0SG1UVw>?	MVrJR\|UxRTNibl2=	MV2yN\|g1PDB\|OB?=
A375	NWTBPIxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L0S\|ExKM7:TR?=	NXSzO5RkPzJiaB?=	M2XPcmROW09?	NEj1O5RKSzVyPUSgcm0>	M{WycVI{QDR2MEO4
DU-4475	M3vaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{H4WFExKM7:TR?=	MkG3O\|IhcA>?	NGnHRpZFVVOR	NX\xTWc2UUN3ME21JI5O	NH\QRZozOzh2NECzPC=>
UACC-257	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XvTVExKM7:TR?=	NYeyRlg5PzJiaB?=	M174UmROW09?	MVvJR\|UxRTZibl2=	M2i0TlI{QDR2MEO4
Colo 205	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml62NVAh\|ryP	MYe3NkBp	MVLEUXNQ	NVzxSItZUUN3ME23JI5O	MVOyN\|g1PDB\|OB?=
SK-MEL-3	NEX6NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlG2NVAh\|ryP	MkTOO\|IhcA>?	MXzEUXNQ	MonLTWM2OD15IH7N	MWqyN\|g1PDB\|OB?=
SH-4	M{Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHhRnUyOCEQvF2=	Mn30O\|IhcA>?	NHOwZZlFVVOR	M2S0[GlEPTB;ODDuUS=>	MYCyN\|g1PDB\|OB?=
A101D	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\WNVAh\|ryP	M4Kyd\|czKGh?	NFHEfHBFVVOR	MkfDTWM2OD17IH7N	MWmyN\|g1PDB\|OB?=
ES-2	NFPrSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	M13FU\|czKGh?	NG\FVodFVVOR	NH3Ob2dKSzVyPUWzJI5O	MWeyN\|g1PDB\|OB?=
HT-29	M3TFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?	NGfrNIo4OiCq	MWXEUXNQ	NEiySWFKSzVyPU[2JI5O	NEDId2EzOzh2NECzPC=>
SW1417	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X6[VExKM7:TR?=	MYS3NkBp	MnjGSG1UVw>?	NVvXbFN3UUN3ME2xOVghdk1?	MnLWNlM5PDRyM{i=
SW872	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLuNVAh\|ryP	M1vTcFczKGh?	MVnEUXNQ	NFe2ZY5KSzVyPUO3O{BvVQ>?	M3PIe\|I{QDR2MEO4
RKO	NWfvdo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\oNVAh\|ryP	NYTSUGl3PzJiaB?=	M3\3S2ROW09?	M2TrWGlEPTB;Mj61NlIh\|ryP	NX7rSIROOjN6NESwN\|g>
A673	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G1PVExKM7:TR?=	NYLyXmp6PzJiaB?=	Mn\ZSG1UVw>?	NXnQdlN7UUN3ME2xNEDPxE1?	NGW0VXQzOzh2NECzPC=>
GCT	NFXIT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHyzc5UyOCEQvF2=	NUXQdY4xPzJiaB?=	NFPaXZJFVVOR	MWTJR\|UxRTFyIN88US=>	M4njVVI{QDR2MEO4
WM-115	M3LSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNEDPxE1?	MVO3NkBp	NXHFWFFRTE2VTx?=	NF23NpFKSzVyPUWgcm0>	MWCyN\|g1PDB\|OB?=
YUMAC	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rR[\|ExKM7:TR?=	MnLZO\|IhcA>?	M1riT2ROW09?	MonGTWM2OD13IH7N	NIK1[lAzOzh2NECzPC=>
OV-90	M{nodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y5dVExKM7:TR?=	M4\jTVczKGh?	MYnEUXNQ	MX\JR\|UxRTJ7IH7N	MmS1NlM5PDRyM{i=
NCI-H508	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W1O\|ExKM7:TR?=	NVT5bZkyPzJiaB?=	MYXEUXNQ	NWTYZYJyUUN3ME2xNEDPxE1?	M3LSXVI{QDR2MEO4
MDA-MB-231	M1zl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zsRVExKM7:TR?=	MYG3NkBp	NIfKOlZFVVOR	NUDReVhPUUN3ME2xNEDPxE1?	Mkm2NlM5PDRyM{i=
SW756	NWTz[XFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XkTVExKM7:TR?=	M{T5ZVczKGh?	M1H4ZWROW09?	M2TuW2lEPTB;MUCg{txO	M4G0OVI{QDR2MEO4
SW-837	NHrwW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxNEDPxE1?	NWDlPVNXPzJiaB?=	MoCwSG1UVw>?	NFXNTZFKSzVyPUGwJO69VQ>?	NWjhN3hmOjN6NESwN\|g>
UMUC-3	NUXsXXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzTNVAh\|ryP	Mo\yO\|IhcA>?	NGnXPGlFVVOR	NYrVeW9oUUN3ME2xNEDPxE1?	NUH4fWpSOjN6NESwN\|g>
LS-174T	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHKWmcyOCEQvF2=	M4LKR\|czKGh?	Mn7sSG1UVw>?	MnjETWM2OD1zMDFOwG0>	MXGyN\|g1PDB\|OB?=
A549	NXjTbHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	NFP5ZlY4OiCq	Mm\hSG1UVw>?	M2DHO2lEPTB;MUCg{txO	NFfUblAzOzh2NECzPC=>
SHP-77	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjHTpMyOTBizszN	M3j6Z\|czKGh?	MoXKSG1UVw>?	MY\JR\|UxRTFyIN88US=>	NFHPUoYzOzh2NECzPC=>
SW480	NGLMbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDnTXAyOCEQvF2=	NGjFVG04OiCq	NELPSYhFVVOR	MoS0TWM2OD1zMDFOwG0>	M1LLblI{QDR2MEO4
DLD-1	M3jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXVNVAh\|ryP	M3zoXVczKGh?	M1z2PGROW09?	NGjESY1KSzVyPUGwJO69VQ>?	NHrqRYUzOzh2NECzPC=>
HCT-116	NE\nV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\QNVAh\|ryP	NXHQXFFYPzJiaB?=	M3jM[2ROW09?	NGf6ZWdKSzVyPUGwJO69VQ>?	NV;nVllJOjN6NESwN\|g>
NCI-H747	NFzBZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvXNVAh\|ryP	M{PkW\|czKGh?	MU\EUXNQ	NYe3cHBLUUN3ME2xNEDPxE1?	MlzaNlM5PDRyM{i=
T-84	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1viclExKM7:TR?=	M3nZTVczKGh?	NVrKVoJNTE2VTx?=	M{HhdGlEPTB;MUCg{txO	MkjMNlM5PDRyM{i=
NCI-H460	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;Zc3lZOTBizszN	MlzsO\|IhcA>?	NFv0OmFFVVOR	MXHJR\|UxRTFyIN88US=>	M2PudVI{QDR2MEO4
Calu-6	NX\aNnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf0fIUyOCEQvF2=	NHf3NHo4OiCq	MVnEUXNQ	MW\JR\|UxRTFyIN88US=>	M2nC[lI{QDR2MEO4
HCC-2998	M4DPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXixNEDPxE1?	NFz1OWc4OiCq	M1m3[mROW09?	NHzP[4tKSzVyPUGwJO69VQ>?	Mlv0NlM5PDRyM{i=
LS1034	NVSyRlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3DNphIOTBizszN	MmTXO\|IhcA>?	MoHhSG1UVw>?	MULJR\|UxRTFyIN88US=>	MYKyN\|g1PDB\|OB?=
CHP-212	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvJNVAh\|ryP	NWPofJV5PzJiaB?=	NX3CXYt4TE2VTx?=	MnG0TWM2OD1zMDFOwG0>	M3;KbVI{QDR2MEO4
SK-N-AS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fLS\|ExKM7:TR?=	MXG3NkBp	NVfX[nZ3TE2VTx?=	M{XTTGlEPTB;MUCg{txO	NXnZe5BlOjN6NESwN\|g>
BFTC-905	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K3[lExKM7:TR?=	MnzaO\|IhcA>?	MnPoSG1UVw>?	MY\JR\|UxRTFyIN88US=>	MnXWNlM5PDRyM{i=
HuT78	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlW2NVAh\|ryP	M1O1TVczKGh?	MXTEUXNQ	NXvSXoNCUUN3ME21NkBvVQ>?	MonuNlM5PDRyM{i=
RPMI-8226	M3rJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjZNVAh\|ryP	M4LoPVczKGh?	NVLMbYxPTE2VTx?=	MUTJR\|UxRTJ4MzDuUS=>	MW[yN\|g1PDB\|OB?=
BC-3	NXzxVG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfS[ngyOCEQvF2=	MoPWO\|IhcA>?	MUDEUXNQ	NWP2VZg{UUN3ME2yO\|chdk1?	MkezNlM5PDRyM{i=
ACHN	NVLZdZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrCbJIyOCEQvF2=	MYO3NkBp	MXvEUXNQ	MlrmTWM2OD1{OUSgcm0>	NFrE[m4zOzh2NECzPC=>
JRT3-T35	NWj4RYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH5W5cyOCEQvF2=	M{nsdFczKGh?	NW\id\|ZOTE2VTx?=	M3fjRWlEPTB;Mkm1JI5O	NYfPR5hxOjN6NESwN\|g>
SK-MES-1	M3jzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj6NVAh\|ryP	MkTXO\|IhcA>?	M1uwWGROW09?	MV;JR\|UxRTN{OTDuUS=>	NIPqbowzOzh2NECzPC=>
CESS	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ONVAh\|ryP	NHr0SXg4OiCq	NYLS[\|BNTE2VTx?=	M{L3PGlEPTB;NEm3JI5O	MlTiNlM5PDRyM{i=
H4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1q5XVExKM7:TR?=	NFjZUHo4OiCq	MnKwSG1UVw>?	NHjjWXJKSzVyPU[xPUBvVQ>?	MlrFNlM5PDRyM{i=
BC-1	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	M1XPN\|czKGh?	MUjEUXNQ	MlPZTWM2OD15MESgcm0>	MlnWNlM5PDRyM{i=
DB	NFX2Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7uOGMyOCEQvF2=	MWm3NkBp	NEO1flNFVVOR	MXPJR\|UxRTh5MzDuUS=>	M376ZlI{QDR2MEO4
RPMI-6666	NV;GNYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTiN2cyOCEQvF2=	MWe3NkBp	NUXFbVd5TE2VTx?=	NIfnOGZKSzVyPUmyPEBvVQ>?	NHHUbHQzOzh2NECzPC=>
MC/CAR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuxNEDPxE1?	NWTUc\|ZpPzJiaB?=	NFjiOGlFVVOR	NFzDPW5KSzVyPUGuNFAzKM7:TR?=	NEDoPJgzOzh2NECzPC=>
SNU-1	M4L5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\2d2cyOCEQvF2=	NEfRfYU4OiCq	NXTGOpBFTE2VTx?=	M13kRmlEPTB;MT61NFEh\|ryP	MXyyN\|g1PDB\|OB?=
CEM/C1	NUTRXmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7TfWwyOCEQvF2=	MUC3NkBp	MoG4SG1UVw>?	NFOwO4FKSzVyPUGuO\|c{KM7:TR?=	NFrINpozOzh2NECzPC=>
GDM-1	M4jTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXWO4ltOTBizszN	NGH5fXM4OiCq	NXXoS21iTE2VTx?=	NFvEU\|ZKSzVyPUGuPVk4KM7:TR?=	NUXjT\|d[OjN6NESwN\|g>
HT-1080	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzsZoEyOCEQvF2=	MmPEO\|IhcA>?	NIrzbZZFVVOR	MlfPTWM2OD1{LkCwOEDPxE1?	MYCyN\|g1PDB\|OB?=
HL-60	M2fVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYSxNEDPxE1?	MmDNO\|IhcA>?	M4HvbmROW09?	MluyTWM2OD1{LkG3PEDPxE1?	MYmyN\|g1PDB\|OB?=
C3A	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmxNEDPxE1?	MVS3NkBp	MnLySG1UVw>?	MXLJR\|UxRTVwNEG0JO69VQ>?	NX\2dZd[OjN6NESwN\|g>
MES-SA	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDEOVVZOTBizszN	MX63NkBp	MnHMSG1UVw>?	NUTZWWtVUUN3ME22Mlk5QSEQvF2=	NHrvd4QzOzh2NECzPC=>
22Rv1	M4Tm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXod\|UyOCEQvF2=	Mom0O\|IhcA>?	NIP1TopFVVOR	M2PY[GlEPTB;MUCg{txO	NXexOWFpOjN6NESwN\|g>
647-V	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxNEDPxE1?	M2KxZlczKGh?	MVPEUXNQ	NXPYbXh2UUN3ME2xNEDPxE1?	NY\NXohSOjN6NESwN\|g>
786-O	NH;PdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPpNVAh\|ryP	NFjiemE4OiCq	MVTEUXNQ	M4rFXGlEPTB;MUCg{txO	M17iPFI{QDR2MEO4
A172	M2D4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;mUFExKM7:TR?=	MXK3NkBp	MkXPSG1UVw>?	NWPxRlhtUUN3ME2xNEDPxE1?	NH7sXGEzOzh2NECzPC=>
A204	NHe5S5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDaSYcyOCEQvF2=	MVK3NkBp	NV\3fpZqTE2VTx?=	NFuxbmlKSzVyPUGwJO69VQ>?	M1TPZlI{QDR2MEO4
A427	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSxNEDPxE1?	MoD0O\|IhcA>?	M1zGUmROW09?	MluyTWM2OD1zMDFOwG0>	NYno[mFxOjN6NESwN\|g>
A431	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfqdI0yOCEQvF2=	NG\YU2o4OiCq	NEnFS\|dFVVOR	M{DhfmlEPTB;MUCg{txO	NF\HZ44zOzh2NECzPC=>
A2780	NEXQRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVv3OZpKOTBizszN	MlPOO\|IhcA>?	NEDLUVNFVVOR	NXfxWZh1UUN3ME2xNEDPxE1?	MWKyN\|g1PDB\|OB?=
ARH-77	NVfa[4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;sW5pmOTBizszN	NYHTTVhKPzJiaB?=	MW\EUXNQ	M1fNfGlEPTB;MUCg{txO	NXn4[GU3OjN6NESwN\|g>
Be(2)C	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe1[FYyOCEQvF2=	MnvyO\|IhcA>?	NHfTW2NFVVOR	NHvsVVBKSzVyPUGwJO69VQ>?	MkjrNlM5PDRyM{i=
BT-20	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG0NVAh\|ryP	NHy3WVc4OiCq	M3Pmc2ROW09?	NUXMZZBlUUN3ME2xNEDPxE1?	M3j4eVI{QDR2MEO4
BxPc3	NYXTXm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fHWVExKM7:TR?=	MmHoO\|IhcA>?	M1LrfmROW09?	M3PsUGlEPTB;MUCg{txO	M{XhdVI{QDR2MEO4
C-4 I	NXLQOYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxNEDPxE1?	NEnPRVI4OiCq	MlnLSG1UVw>?	NYK5VnRCUUN3ME2xNEDPxE1?	M4CzdFI{QDR2MEO4
C33A	NFvqSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHDVJoyOCEQvF2=	NWTLV2hFPzJiaB?=	MWLEUXNQ	M4\NSGlEPTB;MUCg{txO	MkPNNlM5PDRyM{i=
CAL-27	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVexNEDPxE1?	MWS3NkBp	MnT6SG1UVw>?	MVrJR\|UxRTFyIN88US=>	NVzt[mxFOjN6NESwN\|g>
CAL-62	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX4NYoyOCEQvF2=	NH3rb4g4OiCq	M3OxTmROW09?	MVjJR\|UxRTFyIN88US=>	M4jOZ\|I{QDR2MEO4
Calu-3	NIPCZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	MVe3NkBp	M4TFPWROW09?	MVnJR\|UxRTFyIN88US=>	NGDFeY4zOzh2NECzPC=>
CaOV3	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSxNEDPxE1?	NWTEWm1VPzJiaB?=	NEToclNFVVOR	NF7BbGVKSzVyPUGwJO69VQ>?	NGm4UHIzOzh2NECzPC=>
CGTHW1	NFr4N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzJNVAh\|ryP	MVO3NkBp	NUfT[nJCTE2VTx?=	NYC1U3lyUUN3ME2xNEDPxE1?	M{mxblI{QDR2MEO4
CHL-1	NHXSV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[3OFBoOTBizszN	MnvFO\|IhcA>?	NUfhVHRbTE2VTx?=	MmHaTWM2OD1zMDFOwG0>	NWP2[5ltOjN6NESwN\|g>
Colo320DM	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	Mk\LO\|IhcA>?	M3;mWmROW09?	MYPJR\|UxRTFyIN88US=>	MXeyN\|g1PDB\|OB?=
Colo704	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[xNEDPxE1?	NULYNWQ{PzJiaB?=	MWLEUXNQ	MlLZTWM2OD1zMDFOwG0>	MnLsNlM5PDRyM{i=
COR-L23	NGHCOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{THR\|ExKM7:TR?=	MmPhO\|IhcA>?	MoLBSG1UVw>?	NELm[mJKSzVyPUGwJO69VQ>?	NIT5b4UzOzh2NECzPC=>
CRO-AP2	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Ll[FExKM7:TR?=	NIXVeI84OiCq	MVnEUXNQ	MV7JR\|UxRTFyIN88US=>	MUSyN\|g1PDB\|OB?=
Daudi	M332UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr2NVAh\|ryP	NE\EVJY4OiCq	NGG0S5JFVVOR	M4T2Z2lEPTB;MUCg{txO	M3;pfVI{QDR2MEO4
DOTC 24510	NFy5Z3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\IO28yOCEQvF2=	NWezOlR7PzJiaB?=	NEP5SYdFVVOR	MonmTWM2OD1zMDFOwG0>	NI\r[lMzOzh2NECzPC=>
DU-145	M4nEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LaT\|ExKM7:TR?=	NU\abIJGPzJiaB?=	MknnSG1UVw>?	MWfJR\|UxRTFyIN88US=>	MnzYNlM5PDRyM{i=
EB-3	M3nyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2e2fVExKM7:TR?=	NFvvU3g4OiCq	NHLWVGFFVVOR	M3zycWlEPTB;MUCg{txO	MX:yN\|g1PDB\|OB?=
EFM-19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny1NVAh\|ryP	MU[3NkBp	NIfhdJFFVVOR	MYrJR\|UxRTFyIN88US=>	NXPwXGY6OjN6NESwN\|g>
EKVX	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjuR5czOTBizszN	MUm3NkBp	MoPQSG1UVw>?	NVXwcXlpUUN3ME2xNEDPxE1?	NXzZXHFrOjN6NESwN\|g>
FaDu	NGfYeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTxNVAh\|ryP	Ml[3O\|IhcA>?	NFrLSJZFVVOR	M4DFeGlEPTB;MUCg{txO	NUf0TFZpOjN6NESwN\|g>
G401	NHjEZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYKxNEDPxE1?	MmrBO\|IhcA>?	MUHEUXNQ	M3rVfWlEPTB;MUCg{txO	MWeyN\|g1PDB\|OB?=
HCC-70	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LO[lExKM7:TR?=	M{HDbFczKGh?	NYPGdnVMTE2VTx?=	M1r3N2lEPTB;MUCg{txO	MmC1NlM5PDRyM{i=
HCC-1954	NWjYb3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vpWFExKM7:TR?=	M{LUcFczKGh?	NFvxZoZFVVOR	NEDEdnRKSzVyPUGwJO69VQ>?	NWLUXmlkOjN6NESwN\|g>
Hela	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfoN2ZFOTBizszN	M1\pclczKGh?	NGG2[\|dFVVOR	MYXJR\|UxRTFyIN88US=>	NVf4TXdzOjN6NESwN\|g>
Hep3B	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGH0VJoyOCEQvF2=	MWK3NkBp	NWThVFFsTE2VTx?=	NH7WdWpKSzVyPUGwJO69VQ>?	M1X0N\|I{QDR2MEO4
HMCB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnXNZYyOCEQvF2=	MXu3NkBp	NFPqSINFVVOR	MlnxTWM2OD1zMDFOwG0>	M2LVSFI{QDR2MEO4
HN5	NXG3[YlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TY[\|ExKM7:TR?=	NFG3OIc4OiCq	NGjIfI5FVVOR	MYfJR\|UxRTFyIN88US=>	MlLHNlM5PDRyM{i=
HOS	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNEDPxE1?	MUS3NkBp	M1vHcmROW09?	NEnZeFVKSzVyPUGwJO69VQ>?	MXeyN\|g1PDB\|OB?=
HPAF-II	M{W0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTDXXA6OTBizszN	NVjTXmsxPzJiaB?=	NYfwbWF{TE2VTx?=	M4XWN2lEPTB;MUCg{txO	MX2yN\|g1PDB\|OB?=
Hs746.T	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Hv[\|ExKM7:TR?=	MYC3NkBp	NFHWb2pFVVOR	MV;JR\|UxRTFyIN88US=>	M2Ljc\|I{QDR2MEO4
HT	NGfZ[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LINlExKM7:TR?=	M2HIOlczKGh?	MmL3SG1UVw>?	NF;T[ohKSzVyPUGwJO69VQ>?	NH63R4wzOzh2NECzPC=>
HT-3	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHqNVAh\|ryP	MWq3NkBp	NXfKNJFFTE2VTx?=	M1fiTmlEPTB;MUCg{txO	MYiyN\|g1PDB\|OB?=
HuNS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHWSG0yOCEQvF2=	M4S3OVczKGh?	NUHsU4VTTE2VTx?=	M3flc2lEPTB;MUCg{txO	NYLoOlVQOjN6NESwN\|g>
IGROV1	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjNUWFMOTBizszN	Mmm5O\|IhcA>?	MYLEUXNQ	M2DrVmlEPTB;MUCg{txO	M2\SUFI{QDR2MEO4
J82	NIj0Uo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\3cHIyOCEQvF2=	NFS4V5E4OiCq	M13kPGROW09?	M2i0RWlEPTB;MUCg{txO	M2rIWFI{QDR2MEO4
JM1	NWnIRZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPhcoxZOTBizszN	M1HmR\|czKGh?	NFLFTpZFVVOR	NVX1e5NXUUN3ME2xNEDPxE1?	NX[yVYNOOjN6NESwN\|g>
Kato III	NV;vN\|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjFSXZmOTBizszN	NV\F[ItbPzJiaB?=	MYnEUXNQ	NWrSTmRqUUN3ME2xNEDPxE1?	NFO0[pMzOzh2NECzPC=>
KHOS-240S	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33LPVExKM7:TR?=	MU[3NkBp	M{HIemROW09?	M1nwV2lEPTB;MUCg{txO	Mn:1NlM5PDRyM{i=
KM-12	NGn0b3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLCNVAh\|ryP	NFjI[FE4OiCq	M17RSGROW09?	MoroTWM2OD1zMDFOwG0>	MnvhNlM5PDRyM{i=
KPL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITVcXkyOCEQvF2=	MWC3NkBp	NXLxb2tZTE2VTx?=	MlnFTWM2OD1zMDFOwG0>	NYK2UI9vOjN6NESwN\|g>
KYSE-30	NEHBW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrofYIyOCEQvF2=	M3PkO\|czKGh?	M4HiNGROW09?	MXrJR\|UxRTFyIN88US=>	Mmr5NlM5PDRyM{i=
LNCaP	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr1cI4yOCEQvF2=	M4DQT\|czKGh?	NIn5UW9FVVOR	NGTJO4dKSzVyPUGwJO69VQ>?	MUmyN\|g1PDB\|OB?=
MCF-7	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zkXFExKM7:TR?=	NUnQW3BwPzJiaB?=	NEjsUlNFVVOR	MUjJR\|UxRTFyIN88US=>	NITpWWozOzh2NECzPC=>
MC-IXC	M2jhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGOzTIgyOCEQvF2=	MonZO\|IhcA>?	NX3Ge3FyTE2VTx?=	NG\ve\|JKSzVyPUGwJO69VQ>?	NGjUN\|kzOzh2NECzPC=>
MDA-MB-175 VII	MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnCc5oyOCEQvF2=	NInJWoI4OiCq	M17s[mROW09?	MVvJR\|UxRTFyIN88US=>	MoPkNlM5PDRyM{i=
MDA-MB-468	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe2VI4yOCEQvF2=	NFTrVo04OiCq	M{XwfWROW09?	Mon1TWM2OD1zMDFOwG0>	MX:yN\|g1PDB\|OB?=
MiaPaCa	NUm5OXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHv[WgyOCEQvF2=	NYnGfpVtPzJiaB?=	MoP6SG1UVw>?	NVfG[phwUUN3ME2xNEDPxE1?	MV:yN\|g1PDB\|OB?=
Molt-4	NVXEZnJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO1WooyOCEQvF2=	Ml3QO\|IhcA>?	MVzEUXNQ	NGD2[pFKSzVyPUGwJO69VQ>?	MW[yN\|g1PDB\|OB?=
NCI-ADR/RES	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrPUGYxOTBizszN	NYLCTXAzPzJiaB?=	NGGxR3NFVVOR	M4LJXmlEPTB;MUCg{txO	M2PtTFI{QDR2MEO4
NCI-H69	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj1eWMyOCEQvF2=	M4\uWVczKGh?	MlnKSG1UVw>?	MVrJR\|UxRTFyIN88US=>	MViyN\|g1PDB\|OB?=
NCI-H82	NFi5PGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPrdmEyOCEQvF2=	NEPoXYI4OiCq	M3\icmROW09?	MWPJR\|UxRTFyIN88US=>	MkftNlM5PDRyM{i=
NCI-N87	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfGTVVWOTBizszN	MoHBO\|IhcA>?	M4X2NmROW09?	NXrB[ow3UUN3ME2xNEDPxE1?	NVHKdJdFOjN6NESwN\|g>
NCI-H146	NHzvbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXZVJAyOCEQvF2=	NUXKXnhNPzJiaB?=	MVLEUXNQ	M3yzZmlEPTB;MUCg{txO	M1\QUFI{QDR2MEO4
NCI-H157	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLhWnpWOTBizszN	M4G2TFczKGh?	MomzSG1UVw>?	NYDPd3hOUUN3ME2xNEDPxE1?	M{PkO\|I{QDR2MEO4
NCI-H187	NWq4RVZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKxNEDPxE1?	MmiyO\|IhcA>?	NFfBTnRFVVOR	MlzZTWM2OD1zMDFOwG0>	NXixfo46OjN6NESwN\|g>
NCI-H209	M2Oz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrUPVZFOTBizszN	NGPkZ3I4OiCq	MX;EUXNQ	NV60fFRZUUN3ME2xNEDPxE1?	Moq1NlM5PDRyM{i=
NCI-H226	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNEDPxE1?	M3PGblczKGh?	MmS2SG1UVw>?	MnHYTWM2OD1zMDFOwG0>	NGLzOXIzOzh2NECzPC=>
NCI-H292	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	M1;rfFczKGh?	M1jBbGROW09?	M1zlTGlEPTB;MUCg{txO	MlrSNlM5PDRyM{i=
NCI-H322	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlG4NVAh\|ryP	NI[1Wlg4OiCq	MoS1SG1UVw>?	M4XQSmlEPTB;MUCg{txO	M1Lhe\|I{QDR2MEO4
NCI-H358	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjYToUzOTBizszN	MYO3NkBp	M{G0TmROW09?	NX;lU2d4UUN3ME2xNEDPxE1?	M1rKNlI{QDR2MEO4
NCI-H520	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nYb\|ExKM7:TR?=	NYO1TFM1PzJiaB?=	NIPEZoxFVVOR	M1XURmlEPTB;MUCg{txO	NGGxclgzOzh2NECzPC=>
NCI-H526	NW\LcY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPyNVAh\|ryP	M2XJWFczKGh?	MnqySG1UVw>?	MYPJR\|UxRTFyIN88US=>	NGfSZXIzOzh2NECzPC=>
NCI-H630	NWDrb2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrzOIEyOCEQvF2=	MWO3NkBp	NFrpSoRFVVOR	NGjMZZlKSzVyPUGwJO69VQ>?	NFL6fIgzOzh2NECzPC=>
NCI-H661	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf0NpUyOCEQvF2=	MoPQO\|IhcA>?	NGjGfGFFVVOR	MmnRTWM2OD1zMDFOwG0>	MnHmNlM5PDRyM{i=
NCI-H716	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjBWGFVOTBizszN	MX63NkBp	Ml35SG1UVw>?	MUXJR\|UxRTFyIN88US=>	MW[yN\|g1PDB\|OB?=
NCI-H1563	M3rjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\XNVAh\|ryP	NFi3VHU4OiCq	MmnjSG1UVw>?	NIjwOodKSzVyPUGwJO69VQ>?	NHvoc3AzOzh2NECzPC=>
NCI-H1792	NYC0XmlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jZUFExKM7:TR?=	M{D6[\|czKGh?	MVzEUXNQ	NF3QPIFKSzVyPUGwJO69VQ>?	NW\vVYNJOjN6NESwN\|g>
NCI-H2030	NIDh[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnCT5huOTBizszN	NH;VT2U4OiCq	MlviSG1UVw>?	Ml;zTWM2OD1zMDFOwG0>	MmnjNlM5PDRyM{i=
NCI-H2052	NXuzdGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfvNVAh\|ryP	M3O1OVczKGh?	NI\XcWdFVVOR	MV7JR\|UxRTFyIN88US=>	NIm1T5YzOzh2NECzPC=>
NCI-H2122	M1jlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{K2[FExKM7:TR?=	MmHpO\|IhcA>?	M4\KN2ROW09?	NUjUXWhOUUN3ME2xNEDPxE1?	NIS0Z\|AzOzh2NECzPC=>
NCI-H2228	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqxNEDPxE1?	NV7HdlR4PzJiaB?=	NYnSeZlkTE2VTx?=	M1ruV2lEPTB;MUCg{txO	M1rEflI{QDR2MEO4
OE-19	NIrjTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrRNVAh\|ryP	M{LPe\|czKGh?	MoLGSG1UVw>?	MVPJR\|UxRTFyIN88US=>	MYmyN\|g1PDB\|OB?=
OE-21	NGe2TXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn23NVAh\|ryP	MmnXO\|IhcA>?	M3TDfmROW09?	MnrFTWM2OD1zMDFOwG0>	Ml3INlM5PDRyM{i=
OE-33	NYX1OXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TtflExKM7:TR?=	NFGzPJg4OiCq	M4LtOGROW09?	NFnObGNKSzVyPUGwJO69VQ>?	NGXtfY8zOzh2NECzPC=>
OVCAR-3	M17D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnftNVAh\|ryP	MXG3NkBp	NFvjdFhFVVOR	M3L6cWlEPTB;MUCg{txO	NU\Od5RLOjN6NESwN\|g>
OVCAR-4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XQSFExKM7:TR?=	NIS2XYw4OiCq	MmHUSG1UVw>?	MXrJR\|UxRTFyIN88US=>	NEHZ[nQzOzh2NECzPC=>
OVCAR-5	NHOzT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUWxNEDPxE1?	MV23NkBp	NUftZlA4TE2VTx?=	MoPnTWM2OD1zMDFOwG0>	NWjDPGl[OjN6NESwN\|g>
P3HR-1	NFTVZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHTb5AyOCEQvF2=	NWGwXZQxPzJiaB?=	MX;EUXNQ	MXLJR\|UxRTFyIN88US=>	M1PhTlI{QDR2MEO4
PC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorMNVAh\|ryP	MomzO\|IhcA>?	MYHEUXNQ	MoPQTWM2OD1zMDFOwG0>	M3jiU\|I{QDR2MEO4
Raji	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\kNVAh\|ryP	M{i5Z\|czKGh?	NWPRZZU2TE2VTx?=	MkDyTWM2OD1zMDFOwG0>	NI[xXoczOzh2NECzPC=>
RD	NVTYZVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzBN5FDOTBizszN	M17R[\|czKGh?	MYTEUXNQ	NXK1Z4pHUUN3ME2xNEDPxE1?	NEDUR2MzOzh2NECzPC=>
RD-ES	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4S3R\|ExKM7:TR?=	M2q3dVczKGh?	MmXGSG1UVw>?	NXn3XZNpUUN3ME2xNEDPxE1?	NH7Vd3czOzh2NECzPC=>
RL	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXrWYsyOCEQvF2=	NIr5XmQ4OiCq	NXy0fZh4TE2VTx?=	MVHJR\|UxRTFyIN88US=>	MWKyN\|g1PDB\|OB?=
SaOS2	M{jUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3v1bVExKM7:TR?=	M1TZO\|czKGh?	Mm\RSG1UVw>?	MVTJR\|UxRTFyIN88US=>	Mn\MNlM5PDRyM{i=
SCC-9	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTTPFUyOCEQvF2=	MWW3NkBp	Ml6xSG1UVw>?	MlTnTWM2OD1zMDFOwG0>	M17vbFI{QDR2MEO4
SCC-12	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LRTlExKM7:TR?=	NFvxWWU4OiCq	NHf6[IdFVVOR	M17a[mlEPTB;MUCg{txO	NEDERoUzOzh2NECzPC=>
SCC-13	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfMU5dGOTBizszN	MWm3NkBp	NWDRS2l5TE2VTx?=	NF\kfo9KSzVyPUGwJO69VQ>?	MWeyN\|g1PDB\|OB?=
SCC-15	M1vUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmxNEDPxE1?	NYnZUI8{PzJiaB?=	MnPPSG1UVw>?	NVX0dmw6UUN3ME2xNEDPxE1?	NUWzNYRkOjN6NESwN\|g>
SCC-25	NEHv[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr1OWNKOTBizszN	NET2U\|Q4OiCq	NFXYc41FVVOR	NFrzbYJKSzVyPUGwJO69VQ>?	MVqyN\|g1PDB\|OB?=
SCLC-3	NI\ZfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXBfWk1OTBizszN	NY\lTGVIPzJiaB?=	NVXTXYVGTE2VTx?=	MXLJR\|UxRTFyIN88US=>	MXOyN\|g1PDB\|OB?=
SF-268	M2DUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLDc2Y4OTBizszN	M2m2WVczKGh?	NFTpRZdFVVOR	M4TPWmlEPTB;MUCg{txO	MVKyN\|g1PDB\|OB?=
SF-295	NFLWVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoizNVAh\|ryP	NYXYPYx1PzJiaB?=	M1y5SmROW09?	NVzmdlE2UUN3ME2xNEDPxE1?	NGqx[2YzOzh2NECzPC=>
SJRH30	NVXvUoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLTdWdPOTBizszN	NVTveXNvPzJiaB?=	M32zPGROW09?	MlTwTWM2OD1zMDFOwG0>	MXiyN\|g1PDB\|OB?=
SK-BR-3	NUixS\|llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnGxNVAh\|ryP	MWC3NkBp	M2rITGROW09?	MUnJR\|UxRTFyIN88US=>	NGjxRm0zOzh2NECzPC=>
SK-LMS-1	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PBRVExKM7:TR?=	M{W5[FczKGh?	NH65Om5FVVOR	NVPCVZgyUUN3ME2xNEDPxE1?	NUHXOmVUOjN6NESwN\|g>
SK-N-DZ	M2fuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGxNEDPxE1?	NE\kc2I4OiCq	NVS1S4dYTE2VTx?=	NF7ieoxKSzVyPUGwJO69VQ>?	NIXsUIgzOzh2NECzPC=>
SK-N-F1	NHv1SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLlNVAh\|ryP	Mo\iO\|IhcA>?	MYXEUXNQ	NHvzZlRKSzVyPUGwJO69VQ>?	M17BdFI{QDR2MEO4
SKOV-3	NXXDWJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[xNEDPxE1?	MknEO\|IhcA>?	NYD5VmlLTE2VTx?=	NXu0ZYRSUUN3ME2xNEDPxE1?	M{DXOlI{QDR2MEO4
SK-UT-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xNEDPxE1?	MlzUO\|IhcA>?	M{npXGROW09?	NYHYWWczUUN3ME2xNEDPxE1?	NHPadGgzOzh2NECzPC=>
SN12C	NG\lVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nSeFExKM7:TR?=	MYe3NkBp	M17WeGROW09?	NIPDWIZKSzVyPUGwJO69VQ>?	M2fUdVI{QDR2MEO4
SNB-19	NXvnTppST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;nNVAh\|ryP	NEnwdo04OiCq	MUXEUXNQ	M173V2lEPTB;MUCg{txO	NIHBN4MzOzh2NECzPC=>
SNU-5	M2XIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXhcWgyOCEQvF2=	NFf6NXQ4OiCq	NFLmfmhFVVOR	NVrqeox1UUN3ME2xNEDPxE1?	M4PlNFI{QDR2MEO4
SNU-16	M4W2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfvTW8yOCEQvF2=	MVi3NkBp	MoLPSG1UVw>?	MnXVTWM2OD1zMDFOwG0>	NVnPSoFCOjN6NESwN\|g>
SNU-398	NVPKc45{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNEDPxE1?	NX\ycFQ2PzJiaB?=	MXTEUXNQ	NGLWeItKSzVyPUGwJO69VQ>?	MkC0NlM5PDRyM{i=
SNU-449	M3;XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rkUFExKM7:TR?=	NIroTZM4OiCq	MUPEUXNQ	MYPJR\|UxRTFyIN88US=>	NFLDc48zOzh2NECzPC=>
SR	NGq3SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LZfFExKM7:TR?=	MkXJO\|IhcA>?	Mn;CSG1UVw>?	MkfETWM2OD1zMDFOwG0>	Ml7RNlM5PDRyM{i=
ST486	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnEfmg2OTBizszN	MVW3NkBp	MYDEUXNQ	NX;LVWgzUUN3ME2xNEDPxE1?	NH:xXm0zOzh2NECzPC=>
SW579	M2\IZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHSNVAh\|ryP	MVK3NkBp	NEnp[W9FVVOR	NWLSend7UUN3ME2xNEDPxE1?	NFqzcpYzOzh2NECzPC=>
SW684	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\lNVAh\|ryP	MUC3NkBp	M4jDemROW09?	NGGx[ZZKSzVyPUGwJO69VQ>?	Mn3LNlM5PDRyM{i=
SW-780	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIm0PJQyOCEQvF2=	MVG3NkBp	NE\pZ5ZFVVOR	NVvLfpZQUUN3ME2xNEDPxE1?	NF22TngzOzh2NECzPC=>
SW900	NVfwUFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r4bFExKM7:TR?=	NYThbHk5PzJiaB?=	NFfvdHVFVVOR	MUjJR\|UxRTFyIN88US=>	NWH3[4U1OjN6NESwN\|g>
SW1088	M1j6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M374b\|ExKM7:TR?=	M2DmdlczKGh?	MXvEUXNQ	NUfvXJZxUUN3ME2xNEDPxE1?	MkKzNlM5PDRyM{i=
SW1463	M4KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nzXVExKM7:TR?=	NES0doQ4OiCq	MWjEUXNQ	NHHHco9KSzVyPUGwJO69VQ>?	M2D3dlI{QDR2MEO4
SW1990	NXPK[YJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNEDPxE1?	MXe3NkBp	MlvjSG1UVw>?	M3H6dWlEPTB;MUCg{txO	MmD3NlM5PDRyM{i=
T47D	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXoVFNFOTBizszN	MVS3NkBp	M3PaTmROW09?	MkfsTWM2OD1zMDFOwG0>	M2nEW\|I{QDR2MEO4
TE381.T	M3;iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXSxNEDPxE1?	MV63NkBp	NVG0dY1uTE2VTx?=	MWXJR\|UxRTFyIN88US=>	Mk[xNlM5PDRyM{i=
TK-10	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfsNVAh\|ryP	MmLDO\|IhcA>?	MUPEUXNQ	NYrqSFVPUUN3ME2xNEDPxE1?	NW\hdW1lOjN6NESwN\|g>
U2OS	NFT2dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrXT40yOCEQvF2=	MofSO\|IhcA>?	M{HGZWROW09?	M1rTSWlEPTB;MUCg{txO	M2nhZVI{QDR2MEO4
U251	NWjlWnluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[2PXZZOTBizszN	M2LhWlczKGh?	MW\EUXNQ	NH\YRZdKSzVyPUGwJO69VQ>?	MVyyN\|g1PDB\|OB?=
UACC-812	NUfF[lJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13NbVExKM7:TR?=	MlzzO\|IhcA>?	MoPiSG1UVw>?	M{TkOmlEPTB;MUCg{txO	NVnoeVJLOjN6NESwN\|g>
YAPC	NXfudnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3sSFgyOCEQvF2=	NV:4PVduPzJiaB?=	NH\Yc5ZFVVOR	M3nZVmlEPTB;MUCg{txO	M3G0e\|I{QDR2MEO4
ZR-75-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP0d\|kyOCEQvF2=	M1;1OVczKGh?	MkfuSG1UVw>?	NHjQUWtKSzVyPUGwJO69VQ>?	M1vnR\|I{QDR2MEO4
A375	NVezSHhyTnWwY4Tpc44h[XO\|YYm=	MkfuNU4zKM7:TR?=	MmXMOEBp	NYjxb4ROTE2VTx?=	NIT2cXNKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	M{fkWVIzOzh7NEex
YUSIT1	NGLETmFHfW6ldHnvckBie3OjeR?=			NEO0XFRFVVOR	NUPabplSemWmdXPl[EB{\W6\|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh\|ryP	NWnhN4J4OjJ\|OEm0O\|E>
MeWo	M4TsRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M2TiRmROW09?	NXfzR2p3UUN3MDC9JFk5PyCwTR?=	NWns[2RYOjZyMUi1NlQ>
WiDr	NHXHWZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVPEUXNQ	MmGwTWM2OCB;IEe2JI5O	MYKyOlAyQDV{NB?=
Colo-205	MYLGeY5kfGmxbjDhd5NigQ>?	NFLDbpQyKM7:TR?=	MXS0JIQ>	NFiwWohFVVOR	MYTJcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU>	NVrVeYEyOjV\|OEGxOVI>
RBW-1	MmHESpVv[3Srb36gZZN{[Xl?	M{PmS\|Eh\|ryP		NGjpUFdFVVOR	MXvOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NX6yXIdCOjR6OEW2PVA>
RBO-1	NH;0fZZHfW6ldHnvckBie3OjeR?=	M4\BXFEh\|ryP		NYrCdFFwTE2VTx?=	NWnNVmtuUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	M1jTVlI1QDh3Nkmw
RBO-2	NXTlcJJETnWwY4Tpc44h[XO\|YYm=	MnXtNUDPxE1?		NIC0UHZFVVOR	Mn3FTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	MoXHNlQ5QDV4OUC=
RBOW	MWjGeY5kfGmxbjDhd5NigQ>?	NWnDU3RJOSEQvF2=		M2nwU2ROW09?	MnK3TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NHPzSZIzPDh6NU[5NC=>
M257	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITZNpUyODBibl2=	NYLUVpVVPzJiaB?=		Mn:2SI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	MX2yN\|MyPzR2Nh?=
LCP	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzZS25xOTByIH7N	NX;sTHZVPzJiaB?=		NHrFW2RKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	M{T1WVI{OzF5NES2
WM266	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrzUHVyOTByIH7N	MonXO\|IhcA>?		NXnKVG5yUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w	MWCyN\|MyPzR2Nh?=
M257	NV7ifJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIn2[WoyODBibl2=	MoTzO\|IhcA>?		NX\p[o1vTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	NYnVNGFKOjN\|MUe0OFY>
LCP	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TZOlExOCCwTR?=	NEPFUHk4OiCq		Mmi2TY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MWqyN\|MyPzR2Nh?=
WM266	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HDSFExOCCwTR?=	MlnMO\|IhcA>?		NGTMcZJKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36=	MlvmNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03794297	Not yet recruiting	BRAF NP_004324.2:p.V600X\|Erdheim-Chester Disease	National Cancer Institute (NCI)	January 12 2020	Phase 2
NCT03794297	Not yet recruiting	BRAF NP_004324.2:p.V600X\|Erdheim-Chester Disease	National Cancer Institute (NCI)	January 12 2020	Phase 2
NCT03784014	Not yet recruiting	Soft Tissue Sarcoma	Institut National de la Santé Et de la Recherche Médicale France\|Commissariat A L''energie Atomique\|Institut Bergonié\|Plateforme labellisée Inca – Institut Bergonié Bordeaux\|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris\|CIC-EC 1401/EUCLID	March 2019	Phase 3
NCT03784014	Not yet recruiting	Soft Tissue Sarcoma	Institut National de la Santé Et de la Recherche Médicale France\|Commissariat A L''energie Atomique\|Institut Bergonié\|Plateforme labellisée Inca – Institut Bergonié Bordeaux\|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris\|CIC-EC 1401/EUCLID	March 2019	Phase 3
NCT03272464	Recruiting	Melanoma	Massachusetts General Hospital\|Incyte Corporation	November 30 2018	Phase 1
NCT03272464	Recruiting	Melanoma	Massachusetts General Hospital\|Incyte Corporation	November 30 2018	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

Dabrafenib (GSK2118436)

客户使用Selleck该产品发表文献21篇：

客户使用该产品的9个实验数据：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品